Replies to post #558 on Human Genome Sciences, Inc (HGSI)

[rarefind]

« Stock News Overview : ArticleS&P MAINTAINS BUY OPINION ON SHARES OF HUMAN GENOME SCIENCES
2 hours 56 minutes ago - Standard & Poor's
Q4 net loss of $0.41, vs. $0.46, is $0.01 wider than our loss view. Benlysta sales of $25.7M is in line with HGSI's pre-announcement. Although we see limited visibility into Benlysta sales ramp trajectory, we are encouraged by report of positive physician feedback on drug and by HGSI re-affirming profitability target for '14. We expect Benlysta use to expand over time amid lack of lupus options. On narrower Benlysta sales outlook, we widen our '12 loss estimate $0.11 to $1.38, and set '13's at $0.92 loss. On revised forward P/E analysis, we trim our target price to $13.

HGSI is priced right for gains,see you guys over 10 soon and with buy outs in the sector heating up,hgsi could be a morning halt and major gapper anytime.IMO